UBS raises target for Madrigal Pharmaceuticals stock to USD 735.00
Published on 10/24/2026 at 21:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSReporting date November 3, 2026
- UBS raised its Madrigal Pharmaceuticals price target to USD 735.00 from USD 669.00 on October 14, 2026.
- Madrigal Pharmaceuticals expects third-quarter results on November 3, 2026, with USD 404.17 million revenue expected.
- Madrigal Pharmaceuticals stock closed at USD 434.24 on Nasdaq on October 23, 2026, down 4.21 percent from USD 453.34.
- The company had a USD 10.0 billion market capitalization and a USD 393.61 to USD 615.00 52-week range on October 23, 2026.
Madrigal Pharmaceuticals (ISIN US5588681057) has an analyst target of USD 735.00 after UBS raised it from USD 669.00 on October 14, 2026, according to Investing.com. Madrigal Pharmaceuticals stock closed at USD 434.24 on Nasdaq on October 23, 2026, down 4.21 percent from USD 453.34.
UBS lifts the valuation bar
UBS kept a Buy rating and increased its probability of success for Madrigal's F4 program to 60.00 percent from 20.00 percent. The USD 735.00 target stands 69.26 percent above the October 23, 2026 Nasdaq close of USD 434.24, a large gap that reflects expectations for the liver-disease program rather than current earnings.
Revenue is moving before profits
Madrigal reported USD 364.30 million in second-quarter 2026 net sales for Rezdiffra, up 71.00 percent from the same quarter a year earlier, according to Investing.com. The same report said sales exceeded the USD 350.85 million consensus estimate, giving investors a concrete operating counterweight to the company's continuing losses.
What comes next for MDGL?
MarketBeat lists November 3, 2026 as Madrigal's next third-quarter reporting date, with the conference call scheduled for 8:00 a.m. ET. Its consensus calls for USD 404.17 million in revenue and adjusted earnings per share of minus USD 0.8629, versus minus USD 5.08 in the year-earlier quarter.
The company's market capitalization was USD 10.0 billion on October 23, 2026. Its Nasdaq 52-week range was USD 393.61 to USD 615.00, putting the close 10.32 percent above the low and 29.39 percent below the high. The price-to-earnings ratio was negative 33.69, while the company paid no dividend.
Stock position and next date
The combination of a 71.00 percent year-over-year sales increase and a negative earnings multiple leaves the November report as the next measurable test for the valuation. Madrigal Pharmaceuticals is commercializing Rezdiffra for metabolic dysfunction-associated steatohepatitis, while the F4 program remains central to the higher UBS target.
Madrigal Pharmaceuticals stock closed at USD 434.24 on Nasdaq on October 23, 2026, at 4:00 p.m. ET, down 4.21 percent from the prior close of USD 453.34.
Market context: Market report S&P 500.
